Curaleaf Holdings (CURLF) Income towards Parent Company (2019 - 2026)

Curaleaf Holdings (CURLF) posted quarterly Income towards Parent Company of -$293000.0 for Q1 2026, up 97.13% year-on-year from -$148636.3 in Q1 2025, and up 98.13% on a QoQ basis from -$15.7 million in Q4 2025.

Curaleaf Holdings (CURLF) Income towards Parent Company (2019 - 2026) Analysis & Trends

Curaleaf Holdings (CURLF) has reported Income towards Parent Company for 8 consecutive years, with -$293000.0 the latest figure, recorded in Q1 2026.

  • Quarterly Income towards Parent Company rose 97.13% year-over-year to -$293000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.1 million (changed 0.31% YoY) and the FY2025 annual result came in at -$26.2 million, down 152.45% from the prior year.
  • Income towards Parent Company climbed to -$293000.0 in Q1 2026 per CURLF's latest filing, from -$15.7 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for CURLF reached as high as $64.5 million in Q1 2022 and fell as low as -$8.0 billion in Q4 2023.
  • A 5-year average of -$477.8 million and a median of -$7.9 million in 2023 frame the typical range for Income towards Parent Company.
  • Annual changes were most pronounced in 2023 — Income towards Parent Company tumbled 9157.22% — and 2024, when it jumped 106.25%.
  • Year by year, Income towards Parent Company stood at -$86.4 million in 2022, then slumped by 9157.22% to -$8.0 billion in 2023, then surged by 99.86% to -$11.3 million in 2024, then plunged by 38.46% to -$15.7 million in 2025, then soared by 98.13% to -$293000.0 in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$293000.0, -$15.7 million, and -$2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 89.28 Bn 87.42 Bn -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn
10 Curaleaf Holdings 6.95 Bn 6.95 Bn 157.29 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -293,000.00
Dec 31, 2025 -15.66 Mn
Sep 30, 2025 -2.14 Mn
Jun 30, 2025 -3.00 Mn
Mar 31, 2025 -10.19 Mn
Dec 31, 2024 -11.31 Mn
Sep 30, 2024 1.62 Mn
Jun 30, 2024 -1.28 Mn
Mar 31, 2024 567,000.00
Dec 31, 2023 -8.00 Bn
Sep 30, 2023 -25.92 Mn
Jun 30, 2023 -7.90 Mn
Mar 31, 2023 -12.59 Mn
Dec 31, 2022 -86.37 Mn
Sep 30, 2022 -12.73 Mn
Jun 30, 2022 -4.50 Mn
Mar 31, 2022 64.53 Mn
Dec 31, 2021 -5.24 Mn
Sep 30, 2021 62.95 Mn
Jun 30, 2021 76.97 Mn